GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (FRA:23J0) » Definitions » Forward PE Ratio

ProMIS Neurosciences (FRA:23J0) Forward PE Ratio : 0.00 (As of Mar. 22, 2025)


View and export this data going back to 2017. Start your Free Trial

What is ProMIS Neurosciences Forward PE Ratio?

ProMIS Neurosciences's Forward PE Ratio for today is 0.00.

ProMIS Neurosciences's PE Ratio without NRI for today is 0.00.

ProMIS Neurosciences's PE Ratio (TTM) for today is 0.00.


ProMIS Neurosciences Forward PE Ratio Historical Data

The historical data trend for ProMIS Neurosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences Forward PE Ratio Chart

ProMIS Neurosciences Annual Data
Trend
Forward PE Ratio

ProMIS Neurosciences Quarterly Data
Forward PE Ratio

Competitive Comparison of ProMIS Neurosciences's Forward PE Ratio

For the Biotechnology subindustry, ProMIS Neurosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProMIS Neurosciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Forward PE Ratio falls into.



ProMIS Neurosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


ProMIS Neurosciences  (FRA:23J0) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


ProMIS Neurosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProMIS Neurosciences Business Description

Traded in Other Exchanges
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

ProMIS Neurosciences Headlines

No Headlines